Ulrik B. Nielsen
Molecular Biology · 2002–2009
A researcher in the Science corpus: 4 papers; trusts 2 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Molecular Biology — 26 citations into it
- Oncology — 12 citations into it
- Radiology, Nuclear Medicine and Imaging — 6 citations into it
Whom Ulrik B. Nielsen trusts
Their strongest outbound trust, strongest first, inferred from their citations.
- Y. Yarden (in Oncology)
- Boris N. Kholodenko (in Molecular Biology)
Papers from Ulrik B. Nielsen's perspective
Ordered by how strongly the researchers Ulrik B. Nielsen trusts endorse each paper. Same corpus, a different order for every researcher.
- Untangling the ErbB signalling network (Nature reviews. Molecular cell biology)
- Computational modeling of the dynamics of the MAP kinase cascade activated by surface and internalized EGF receptors (Nature Biotechnology)
- Cell-signalling dynamics in time and space (Nature reviews. Molecular cell biology)
- Phosphotyrosine interactome of the ErbB-receptor kinase family (Molecular Systems Biology)
- Prediction and validation of the distinct dynamics of transient and sustained ERK activation (Nature Cell Biology)
- BioNetGen: software for rule-based modeling of signal transduction based on the interactions of molecular domains (Bioinform.)
- EGF–ERBB signalling: towards the systems level (Nature reviews. Molecular cell biology)
- Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. (New England Journal of Medicine)
- The problem of synergism and antagonism of combined drugs.
- The segment polarity network is a robust developmental module (Nature)
Their papers
- Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. (2006) — 1,079 citations
- Systems biology and combination therapy in the quest for clinical efficacy (2006) — 582 citations
- Input–output behavior of ErbB signaling pathways as revealed by a mass action model trained against dynamic data (2009) — 437 citations
- Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. (2002) — 683 citations